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Genome-wide analysisTesticular germ cell tumors (TGCT) represent the most common malignancy among young males. To our
knowledge no comprehensive Copy Number Variation (CNVs) studies of TGCT using high-resolution Single
Nucleotide Polymorphism (SNP) array have been performed. By a genome-wide analysis of CNV and loss of
heterozygosity (LOH) in 25 primary seminomas, we conﬁrmed several previously reported genomic
alterations and discovered eight novel genomic alterations including ampliﬁcations and homozygous
deletions. Moreover, a comparison of genomic alterations of early and late stage seminoma identiﬁed CNVs
that correlate with progression, which included deletions in chromosomes 4q, 5p, 9q, 13q and 20p and
ampliﬁcations in chromosomes 9q and 13q. We compared previously perform Affymetrix expression analysis
in a subset of samples and found robust correlation between expression and genomic alterations.
Furthermore, high correlations (40–75%) were observed between CNV by SNP analysis and quantitative
PCR. Our ﬁndings may lead to better understanding of TGTC's pathogenesis.onal Institutes of Health (NIH)/
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Testicular germ cell tumors (TGCT) represent the most common
malignancy among young Caucasian males between the ages of 15 to
40 years and account for the highest cancer related cause of death in
this age group [1]. The incidence of testicular cancer has substantially
increased in the USA (www.cancer.gov). White men are ﬁve times
more likely than African American men to develop testicular cancer,
thus indicating a genetic predisposition for this disease. In the United
States, approximately 8400 newly diagnosed testicular cancer cases
and 380 deaths are expected in 2009.
Based on their degree of differentiation and histological char-
acteristics TGCT can be classiﬁed into seminomas (SE) and non-
seminomas (NS), as well as combinations of these [2,3]. SE resembling
primordial germ cells and NS composed of neoplastic tissues exhibitsomatic, embryonal or extra-embryonal differentiation [4]. SE and NS
are thought to arise from pre-invasive carcinoma in situ (CIS), also
referred to as intra-tubular germ cell neoplasia (IGCN) unclassiﬁed.
Details on the pathogenesis of SE and NS were reviewed previously
[5,6]. SE represent approximately 40% of diagnosed cases [7]. Up to
32% of patients with SE clinical stage I can relapse if no adjuvant
treatment is given. Nevertheless, the cure rate in patients with stage I
SE is almost 100% and can be achieved with three accepted strategies:
adjuvant radiotherapy, single-agent carboplatin chemotherapy or a
surveillance strategy. Around 28% of the patients that present with
seminoma have regional or distantmetastasis (http://seer.cancer.gov/
statfacts/html/testis.html), of those with distant metastasis, the
survival rate in 5 years is around 70%.
There are four main types of NS tumors: embryonal carcinoma, yolk
sac tumor, immature or mature teratoma, and choriocarcinoma. These
tumor types are often seen together in various combinations, referred to
as mixed TGCTs, which may also include a SE component [8].
Several studies have provided insight into the progression of TGCTs
although few studies have identiﬁed the underlying genes involved in
the pathogenesis of testicular cancer [5,6]. Over-representation of
chromosome12p is common inTGCTsbut is not seen inCIS, suggestinga
critical role for this ampliﬁcation in TGCT progression [9]. A progressive
genomic instability correlating to the stage of the disease has also been
previously described including gains of DNA material from whole
chromosomal armsof 1q, 7p, 7q, 8p, 8q, 12p, 12q, 14q, 15q, 21q, and 22q
Table 1
Clinical and pathological characteristics of the seminoma cancer patients (N=25).
Sample no. All loci Normal Tumor Stage Age
SE1 95.22% 96.94% 93.49% 1 30
SE2 94.44% 96.14% 92.73% 1 31
SE3 97.26% 98.68% 95.83% 1 60
SE4 96.74% 96.65% 96.83% 1 45
SE5 96.05% 95.86% 96.24% 1 30
SE6 88.43% 93.29% 83.56% 1 28
SE7 91.21% 91.61% 90.80% 1 47
SE8 86.13% 84.91% 87.34% 1 45
SE9 88.04% 82.49% 93.59% 1 38
SE10 97.16% 98.64% 95.68% 1 29
SE11 96.03% 94.94% 97.11% 1 42
SE12 96.23% 97.81% 94.65% 1 60
SE13 95.25% 93.87% 96.62% 1 29
SE14 95.81% 93.52% 98.09% 1 30
SE15 93.02% 95.34% 90.70% 1 32
SE16 70.15% 75.72% 64.58% 1 39
SE17 95.38% 93.42% 97.33% 1 33
SE18 78.52% 78.52% 78.51% 1 26
SE19 88.23% 92.28% 84.18% 2 32
SE20 94.08% 96.60% 91.56% 2 32
SE21 92.33% 90.98% 93.67% 2 39
SE22 97.09% 97.46% 96.71% 2 39
SE23 89.63% 95.45% 83.80% 3 40
SE24 96.68% 95.44% 97.91% 2 39
SE25 96.68% 95.44% 97.91% 2 48
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SE, gain of 12p is the most striking alteration observed [12]. A recent
study demonstrated that the loss of PTEN expression marks the
transition from noninvasive IGCN to invasive cancer, being PTEN
expression retained in IGCN, the presumed precursor lesion of germ
cell tumors, and lost in tumors [13].
DNA copy number alterations and/or changes in allelic ratios are
hallmarks of different subsets of neoplasia [14]. In the past, various
techniques such as Comparative Genomic Hybridization (CGH) arrays,
microsatellite analysis and Fluoresence in situ hybridization (FISH)
were used to identify novel genomic alterations, such as ampliﬁcation,
deletions, and translocations, however these techniques had limita-
tions which included the inability to detect loss of heterozygosity
(LOH) that were not directly a result of deletions and a small detection
range (1–20 kb). The introduction of FISH overcame these limitations
of conventional cytogenetic analysis, however this technique was not
high throughput and required probes with high speciﬁcity [15]. CGH
arrays were the ﬁrst improved high throughput assays that facilitated
the analysis of genome wide localization of chromosomal imbalances
without prior knowledge of speciﬁc regions of genomic damage [16].
They also provided the ability to investigate highly fragmented DNA
often obtained from formalin ﬁxed tissues [17]. In addition, detection
of ampliﬁcations less than 1 Mb were relatively high, however the
resolution of regional deletions, especially homozygous ones,
remained limited [18]. Furthermore, CGH has limits of deﬁnition for
small losses and cannot distinguish between paternal and maternal
recombination events [19,20].
Microsatellite instability has been well established as a mechanism
for the development of many diseases including cancer [21]. Micro-
satellite analysis is beneﬁcial in elucidating microsatellite instability,
gene dosage and kinship. This technique can be tedious and uses
relatively large amounts of DNA. Another important limitation was the
occurrence of “null alleles” in which the microsatellite primers failed to
amplify in PCR reactions, due to pointmutations [22]. Furthermore, PCR
failure occasionally results in heterozygous individuals being scored as
homozygous. The introduction of single nucleotide polymorphism
(SNP) array technology allows for combined detection of both copy
number and LOH information throughout the genome at greater
resolution thanprevious techniques [23,24]. In addition, this technology
is high throughput and permits the ﬁne mapping of copy number
changes with a range of 30–900 kb [24].
Although testicular cancer is highly responsive to cisplatin, 10–20% of
metastatic patients will not achieve a complete remission after the ﬁrst
treatment, due to incomplete response or tumor relapse [25]. The
sensitivity of TGCTs to chemotherapeutic drugs may lay in the
susceptibility of germ cells to apoptosis which makes this cancer type
an ideal tumor type model to investigate and understand the molecular
determinants of chemotherapy sensitivity of solid tumors. Attempts to
develop personalizedmedicine treatments for solid tumors could beneﬁt
of better understanding of the biology and genetic alterations in TGCTs.
The availability ofmicroarray-basedhigh-resolutionSNPanalysis allows a
reproducible and rapid determination of genome-wide allelic changes
such as genomic instability and LOH from a single DNA sample. This
technique has been employed for SNP genotyping in various human
cancers [23,26–28] and in this report, we present the ﬁrst data using the
SNPmicroarraymapping technique to characterize SEDNA samples from
25 patients, the most common subtype of testicular cancer.
2. Materials and methods
2.1. Sample collections
We used collected samples from the Erasmus MC — University
Medical Center Rotterdam (Daniel den Hoed Cancer Center), Depart-
ment of Pathology, The Netherlands. The use of tissues for scientiﬁc
purposes included in this studywere approvedbyan institutional reviewboard (MEC02.981 andCCR2041), and the sampleswere used according
to the “Code for Proper Secondary Use” (FMWV) (version 2002). Brieﬂy,
primary tumor and peripheral blood samples were collected from 25
patients undergoing surgical resection of testicular SE (Table 1). Two
samples were excluded for further analysis due to low call rate. Tumor
samples were promptly frozen at−80 °C after initial gross pathological
examination. DNA was isolated from tumor tissue and lymphocyte
pellets by standard SDS/proteinase K digestion followed by phenol and
chloroform extraction and ethanol precipitation. Approval for research
on human subjects was obtained from The Johns Hopkins University
Institutional Review Boards. This study qualiﬁed for exemption under
the U.S. Department of Health and Human Services policy for protection
of human subjects [45 CFR 46.101(b)].
2.2. SNP mapping assay
Genomic alterations in tumor samples were genotyped using
250 K Nsp1 SNP arrays (Affymetrix). A detailed protocol is available
on the Affymetrix web page (http://www.affymetrix.com/support/
technical/manuals.affx). Brieﬂy genomic DNA from tumor and paired
lymphocyte were restriction digested with Nsp1, ligated to the
adaptor, and ampliﬁed by polymerase chain reaction (PCR) using a
single pair of primer. After puriﬁcation of PCR products with the
MinElute 96 UF PCR puriﬁcation kit (Qiagen), amplicons were
quantiﬁed. 100 μg of PCR ampliﬁed DNA was digested with DNase I
to sizes ranging from 200 to 1000 bp. Fragmented PCR products were
labeled with biotin and hybridized to the array. Arrays were then
washed on Affymetrix ﬂuidics stations. The bound DNA was
ﬂuorescently labeled using streptavidin–phycoerythrin conjugates
and scanned using Gene Chip Scanner 3000. Hybridization, scanning
and raw analysis were performed by the Microarray Core facility at
Johns Hopkins School of Medicine.
2.3. Data analysis
CEL ﬁles containing intensity value for each of the probes on the NspI
250 K chips were generated using GeneChip Operating Software
(Affymetrix Inc., USA). The allelic intensity of each SNP from theGeneChip
Operating Software was measured using the GeneChip Genotyping
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were done using BRLMM-P algorithm for each of the SNPs.
For further analyses, we utilized the copy number analysis
protocol from Partek Genomic Suite™ (ver 6.4., http://www.partek.
com/partekgs). Brieﬂy, the CEL ﬁles were imported onto copy number
analysis pipeline and subsequently normalized to baseline reference
intensities using 270 HapMap samples to infer the paired allele ratio
for each of the samples (for both tumor and normal samples).
Additionally, for better inference of copy number estimates, we used
genomic smoothing in order to reduce variance in the array data.
Hidden Markov models (HMM) assuming diploid copy for normal
samples were employed to infer the copy number estimates in tumor
samples. Delineating copy number change and its boundaries can
often be challenging. To guard against detection of false positive CNVs
arising due to inherent microarray “noise”, we utilized a genomic
segmentation algorithm (requiring a minimum of 10 probes) to
characterize isolated islands of signiﬁcantly higher or lower intensity
ratios into cancer speciﬁc copy number alteration regions. A threshold
of ≥3 and ≤1.25 was used to categorize altered regions as copy
number gains (ampliﬁcation) and copy number losses (deletions),
respectively. Student's t-testswere performed to identify stage speciﬁc
(stage 1 vs. stage II+III) copy number altered regions.
For LOH analysis, we utilized the algorithm incorporated in dChip
software [12]. The LOH events were estimated with regard to
informative markers in the different chromosomes, and an average
probability was calculated based on prevalence of LOH events across
all our samples. As we hadmatched normal DNA available from all our
samples, a matched pair analysis (based on SNP by SNP genotypes)
was employed for the detection of LOH regions.
For further analysis in our regions of interest, we performed a ﬁne-
scale mapping of the copy number altered regions to identify speciﬁc
regions of allelic imbalance (Fig. 1). Each of the genotypes was
compared and regions/SNPs showing somatically altered genotypes
(based on paired SNP by SNP comparison) were identiﬁed and
annotated for the presence of cancer associated genes (e.g., tumor
suppressor genes, oncogenes etc.).
Annotation information for SNPs andgenomic locationswere carried
out using the human genome build 17 (hg17) and the widely used and
available online databases (Netaffyx: http://www.affymetrix.com;
Ensembl: http://www.ensembl.org; UCSC: http://genome.ucsc.edu).
2.4. Affymetrix expression array
Affymetrix arrays were performed in a subset of SE samples (from
Table 1) for gene expression proﬁling per the manufacturer's
instruction in our previous study [29]. We used Affymetrix GeneChip
Human Genome U133A plus 2.0 Arrays containing N22,000 probe sets
for the analysis of N18,400 transcripts, which include ~14,500 well-
characterized human genes. Biotinylated RNA probe preparation and
hybridization were previously described [30].
2.5. Quantitative PCR validation
SNP array data was validated by real-time quantitative PCR using
the ABI Prism 7900HT Sequence Detection System [31] and Roche
SYBR green kit. Genes FAT3, EDNRB1 and ALKBH8 were chosen from
deleted areas and gene RASSF8 is chosen from ampliﬁed area. Primers
were designed by using Primer3 and the human genome reference
assembly (UCSC version hg17, based on the National Center for
Biotechnology Information build 35). All samples were run in
triplicate. Copy number alterations were assessed by relative
quantiﬁcation methods that compensate for differences in target
and reference ampliﬁcation efﬁciencies. The reference tissue used for
the copy number calculations was from the same individual from
whom the tumor sample was taken. Primer sequences and PCR
cycling conditions are detailed in Supplemental Table 1.The number of copies corresponding to the gene of interest was
determined by real-time quantitative PCR with a 7900HT Sequence
detector (Perkin-Elmer Applied Biosystems). Brieﬂy, PCRs were carried
out in a reaction volume of 10 μl using FAST SYBRGreen (Qiagen). 20 ng
of DNAwas used in each real-time PCR reaction. The conditions used for
ampliﬁcationwere: one cycle of 95 °C for 3 min, followed by50 cycles of
95 °C for 15 s and58 °C for 1 min.Reactionswere performed in triplicate
and the average of the threshold cycle values was calculated. DNA
content was normalized to that of Line-1 — a repetitive element for
which copy numbers per diploid genome are similar in normal or
neoplastic human cells [32,33]. Changes in copy number were
calculated as: 2(Dt−Dline)− (Nt−Nline) as published previously [33],
where Dt is the mean threshold cycle number for experimental primer
in DNA extracted from tumor cells, Dline is the mean threshold cycle
number for Line-1 primer in DNA extracted from tumor cells, Nt is the
threshold cycle number in reference DNA, and Nline is the threshold
cycle number for Line-1 primer in reference DNA.
3. Results
3.1. Identiﬁcation of novel copy number alterations in seminoma
We examined tumor and paired normal lymphocyte DNA from 25
patients diagnosed with a primary testicular SE with a 250 K Nsp1
platform array for genomic alterations. Clinico-pathological and
demographic information of these patients are provided in Table 1.
Initially, we identiﬁed 1810 potential copy number (CN) altered
regions in our cohort using SNP array. The putative CN altered regions
were further ﬁltered based on number of probes (≥10) and Hidden
Markov Model (HMM) segmentation to delineate CN altered regions
and plausible gene candidates which included RASSF8, ALKBH8,
EDNRB1 and FAT3 (Supplementary Fig. 1).
The signal intensity of each SNP probe along the chromosomeswas
detected and normalized with normal tissue to calculate the genome-
wide distribution of DNA copy number alterations. The average signal
intensity for normal tissues was 2.0. Cutoffs of copy number
boundaries used were b1.5 and N2.6 for deletions and ampliﬁcations
respectively. A heat map depicting genome-wide CN proﬁle in all SE
samples is shown in Fig. 1. The frequency of imbalances shown at the
top of the ﬁgure depicts CN intensity ratio (log2 ratio) for all samples
on a representative color gradient scale. Compared to normal
lymphocyte DNA, SE samples show wide spread copy number gains
and losses involving all chromosomes. Detectable gains in chromo-
somes 2, 3, 7, 8, 12 and X and losses in 4, 5, 11, 13, 18 and 20 were
observed (Fig. 1, red=gain; blue=loss).
Inferred copy number changes were observed by ﬁne mapping on
chromosome 13q (deletion; ~40%), which encodes EDNRB1 (Fig. 2A,
upper panel) and 11q (FAT3) (Fig. 2B, upper panel). Chromosome 12p
indicated high level ampliﬁcation (~60% of our samples) and encodes
for RASSF8 gene (Fig. 2C, upper panel). Both deletion of 11q and gain
of 12p are known to be altered in testicular cancer [34,35]. We also
performed ﬁne mapping of our novel ampliﬁcation region in
chromosome 2 (Supplemental Fig. 2). Samples 16, 17, 19 and 21 all
indicated ampliﬁcation in tumor compared to normal. In addition, we
identiﬁed a novel deletion in chromosomal region 20p12. In general,
allelic imbalance was more common in SE stages II–III than in stage Ι
tumors. An overview of genomic alterations in SE found in SNP array
analysis in our study is shown in Table 2. Novel genomic alterations
discerned in this study are on chromosomal arms 2q14, 2q22, 2q23,
2q24, 2q32 and 20p11–12 harboring≥17% frequency of copy number
gains (Table 3). Candidate genes found in regions 2q14–35 included
ERCC3, XIRP2, IKZF2 and CRYGC. IKZF2 is a stress related gene that has
been shown to be aberrantly expressed in various lymphomas and
leukemia [36]. Candidate genes found in 20q11–12 included ESF1,
C20orf7, SEL1L2, and MACROD2. ESF1 has been shown to be required
for 18S rRNA synthesis in S. cerevisiae [37].
Fig. 1. Genome-wide distribution of DNA copy number alterations in seminoma. Copy number (CN) alterations are depicted in color gradients corresponding to DNA; CN gains
(ampliﬁcations — red) and CN losses (deletions — blue). The top panel shows frequency distribution of all the CN changes across all 23 chromosomes. The bottom panel shows the
intensity plots showing each of the samples.
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For validation of SNP array based data, RASSF8, FAT3, ALKBH8 and
EDNRB1were selected for validation from 77 cancer speciﬁc somatic CN
altered regions. The chromosomal locations of the later genes are on
12p12, 11q14.3, 11q22.3 and 13q22.3 respectively. The frequencies of
genomic alterations of these regions by SNP array analysis are shown in
Table 2. The number of copies corresponding to RASSF8, FAT3, ALKBH8
and EDNRB1 locus were examined by Quantitative-PCR (QPCR).
Representative ampliﬁcation curves for EDNRB, FAT3 and RASSF8 are
shown in lower panel of Fig. 2 A, B and C respectively. ALKBH8, EDNRB1
and FAT3 copy number losses (b1.5) were detected in at least 39% of all
23 samples. The relative ﬁndings of the SNP array compared to theQPCR were at least 40% consistent (Table 4). Homozygous deletions
(HD, less than b0.5 copy) by both the SNP array and QPCR methods
were found for ALKBH8 (21%) and FAT3 (36%) in our samples,
suggesting that these genes are potential tumor suppressor genes
(TSGs) for SE and need to be explored in further studies.
3.3. Comparisonof copynumber alterations and expression of related genes
After conﬁrming the SNP data with QPCR, we compared
these genetic alterations with Affymetrix expression array data
that was undertaken by a separate study [29]. Consistent ﬁndings
were observed for genes FAT3, RASSF8 and ALKBH8 (Supplementary
Fig. 3).
Fig. 2. FinemappingonsigniﬁcantCopyNumber(CN) alterations in seminoma tumors. (A). Inferredcopynumberof stage1matchednormal-tumorspair showinghemizygousdeletionsof
EDNRB (chromosome 13 band q22.3). The dark and light grey shaded points are inferred copy number estimates for matched normal and tumor samples, respectively. (B). Inferred copy
number changes (deletions) on chromosome 11 band q14.3 encompassing the putative tumor suppressor gene FAT3. (C). High level ampliﬁcation on the short arm of chromosome 12, a
region previously reported to be highly ampliﬁed in seminoma.
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Although many chromosomal alterations in testicular cancer have
been identiﬁed, no data exist correlating these changes to disease
progression. Our data suggest that CN deletions in chromosomes 4, 5,Table 2
Cancer speciﬁc genomic alterations (ampliﬁcations and deletions) seen in seminoma samp
pathway are listed here.9, 13, and 20 and ampliﬁcations of chromosomes 9 and 13 associated
with advanced stage (stages II/III vs. stage I) of the disease and details
are found in Table 5. A deletion of chromosome 13q13.3 which
encodes for DCLK1 and SOHLH2 was altered in 20% of the samples.
SOHLH2 is a germ cell speciﬁc transcription factor that may be ales (N=23). The plausible candidates that may play a role in testicular carcinogenetic
Table 3
Novel alterations of chromosomal regions in seminoma.
Region CNV Alteration Frequency Genes Candidate gene function Samples
2q24.1 amp 13% UPP2 Folliculogenesis, hormone secretion regulation, 6, 16, 17, 20, 21, 24
2q14.3 amp 26% CYP27C1, ERCC3, MAP3K2 CYP27C1 — only expressed in testis;
ERCC3 — DNA repair enzyme NER
6, 16, 17, 19, 21, 24
amp 22% MKI67IP, TSN TSN — chromosomal translocations and regulation of RNA
expression
16, 17, 19, 21, 24
2q22.1 amp 17% THSD7B Unknown 16, 17, 21, 24
2q23.3 amp 17% NEB, ARL5A NEB — Calcium/CaM regulation 16, 17, 21, 24
26% XIRP2 DNA repair 6, 17, 19, 20, 21, 24
2q32.1 amp 22% ELF2P4, FSIP2 FSIP2 — spermatocyte development 6, 17, 19, 21, 24
26% SLC23A3, ABCB6 STK16 — involved in VEGF expression regulation,
ABCB6 — drug transporter ATP dependent, expressed in testis
and linked with breast cancer
16, 17, 19, 20, 21, 24
2q33.3 amp 26% CRYGEP1, CRYGC, CRYGB, CRYGA Stress response 6, 17, 19, 20, 21, 24
2q34 amp 26% IKZF2 Aberrant expression in Hodgkins and non-Hodgkins lymphoma 6, 16, 17, 19, 21, 24
20p12.1 del 13% ESF1, C20orf7, SEL1L2, MACROD2 ESF1 — pre-RNA processing 3, 15, 16
able 4
nalysis of ALKBH8, FAT3, EDNRB1 and RASSF8 copy number: The number of copies
rresponding to ALKBH8, FAT3, EDNRB1 and RASSF8 locus was determined by real-time
uantitative PCR. The % correlation between the SNP array and QPCR is indicated at the
ottom of the table. The total number of altered samples was divided by the total
umber of samples to determine the % of deletions (blue) and ampliﬁcations (red).
A=QPCR not available. A) For deleted region the correlation between SNP analysis vs.
PCR were 75%, 71% and 75% for ALKBH8, FAT3 and EDNRB1 respectively B) For
mpliﬁed region the correlation between SNP analysis vs. QPCR was 40% for RASSF8
cus.
Sample ID ALKBH8 FAT3 EDNRB1 Sample ID RASSF8
SE2 0.457 NA 0.5697 SE2 1.3
SE5 0.388 1.341 0.67102 SE3 NA
SE6 0.858 3.04 1.431 SE5 1.01
SE8 0.962 0.42 1.085 SE6 4.14
SE10 2.28 0.506 1.128 SE8 0.63403
SE12 2.09 NA 1.996 SE10 0.523
SE15 0.805 0.686 0.6743 SE12 1.94
SE16 4.29 0.806 1.427 SE15 3.183
SE17 1.803 0.377 1.094 SE16 1.62
SE18 0.885 0.584 1.052 SE17 1.943
SE19 1.33 1.875 1.244 SE18 4.11
SE20 2.116 0.6565 2.416 SE19 1.57
SE22 NA 2.3 NA SE23 1.151
SE23 0.599 0.1524 0.968 SE24 2.49
SE24 1.105 0.0247 NA
Consistency 75% 71% 75% 40%
(A) Deleted region (B) Amplified region
etween SNP array and QPCR analysis.
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most of the genetic alterations that correlated with advance stage
disease related to deletions.
3.5. LOH
Paired DNA samples from the same patient allowed us for the
identiﬁcation of regions of LOH in the tumor samples. Alterations
associated with copy number losses and gains were found to be
associated with LOH in 12 chromosomal regions. Frequencies of LOH
regions are detailed in Table 6. Detectable LOH regions were identiﬁed
on 2p15, 2q21, 2q32, 2q35, 3p26, 4q13, 5q21, 8q11, 9q21, 11q2, 13q1
and 18q12.2 (Table 6). Interestingly, we identiﬁed 30 homozygous
deletions (HD) in the only stage III SE analyzed. The most important
HDs centered on chromosome 4 (deleted gene: UNC5C), chromosome
6 (deleted gene: NKAIN2), chromosome 8 (deleted gene: CSMD1) and
chromosome 12 (deleted gene: IPO8). We also detected 43 focal
ampliﬁcations, although no alteration was common among our
samples. Supplemental Fig. 4 shows heat map inferred LOH calls
based on dChip software analysis using the paired tumor and normal
samples.
4. Discussion
Prior studies have investigated genomic alterations in testicular
cancer by means of CGH and microsatellite marker analysis in both
testicular cell lines and tissue samples, however to our knowledge; no
large scale study has been performed on SE using high resolution SNP
arrays. Gene ampliﬁcations and deletions are one of the major
mechanisms of oncogene activation and TSG inactivation in cancer
development, respectively. The goal of our study was to identify new
genomic regions of alterations by analyzing 25 SEs with matched
normal DNA by using a 250 K Nsp1 array. We hypothesized that using
a highly sensitive technique such as Affymetrix 250 K Nsp1 array; we
could detect small unidentiﬁed regions that may have been
undetectable using previous techniques. These newly discovered
regions could in turn provide valuable information on speciﬁc genes
that are deregulated throughout the different stages of SE. This
information could be a useful avenue to understand the biology of SE
and also help with the discovery of biomarkers such as for early
detection and therapy response prediction. Using paired samples we
found chromosomal copy number gains and losses to be in agreement
with previous ﬁndings [39,40]. In addition, we identiﬁed eight novel
regions of copy number gains (2q14.3, 22.1, 23.3, 24.1, 32.1, 33.3, and
34) and losses (20p12.1). However, the biologic importance of the
genes positioned in these altered regions remains to be determined.
Copy number losses for 20p were recently reported in colorectal
cancer, Barrett's adenocarcinoma and neuroblastoma [24,41,42].Allelic losses of chromosome 2q were previously reported in TGCT
cell lines [40], albeit we found gain in this region. The inconsistency
may be due to uses of cell lines vs. a primary tumor tissue specimens
and different technique and stringent conditions were used to deﬁne
losses and gains.
Although we did not perform any formal correlation study
between CNV and mRNA expression, by our initial comparison
analysis among CNV and mRNA expression we observed that
expression and CNV correlate for several genes like FAT3, RASSF8
and EDNRB1. Comprehensive analysis of CNV and mRNA expression
may identify a panel of promising genes and those may represent the
“driver genes” among a sea of “passenger genes” that were aberrant.
Other confounding factors include epigenetic alteration such as
methylation and miRNA expression that may have a signiﬁcant
contribution to the steady-state gene expression levels even in the
setting of gene copy number changes. This hypothesis can be tested
when methylation and miRNA expression data on the same samples
become available; a study currently undertaken.T
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Table 5
Genomic alterations that correlate with progression seen in seminoma samples
(N=23). The plausible candidates that may play a role in testicular carcinogenetic
pathway are listed here.
Chr Cytoband %
samples
# of
markers
Genomic
alteration
Transcribed genes
4 4q35.1 16 15 Deletion MGC45800
5 5p15.1 16 19 Deletion ZNF622, FAM134B
9 9q31.3 16 105 Deletion ACTL7A, ACTL7B, IKBKAP,
C9orf6, ACRP, CTNNAL1,
C9orf5, CS266556, AL390170,
C9orf4, AX747119, EPB41L4B,
PTPN3
9 9q22.31 16 18 Ampliﬁcation FAM120A, PHF2
9 9q33.1 16 30 Deletion TLR4
9 9q21.31 16 10 Deletion ENSG00000218149
9 9q21.33 16 10 Deletion NTRK2
13 13q13.3 20 14 Deletion DCLK1, SOHLH2
13 13q34 16 6 Deletion ARHGEF7
13 13q22.3 16 51 Deletion SCEL, SLAIN1, EDNRB1,
BX647243, AK090854
13 13q22.2 16 35 Deletion TBC1D4, COMMD6, MST076,
UCHL3
13 13q12.13 12 16 Ampliﬁcation ATP8A2
13 13q22.2 12 5 Deletion LMO7
20 20p12.1 16 19 Deletion ESF1, C20orf7, SEL1L2,
MACROD2
20 20p11.21 12 16 Deletion NXT1
347C. LeBron et al. / Genomics 97 (2011) 341–349We conﬁrmed our SNP array data by quantitative PCR. Several
genes from altered regions were randomly selected for validation
study. These genes include FAT3 (chromosome 11q), BTG3 (chromo-
some 21q), ALKBH8 (chromosome 11q), RASSF8 (Chromosome 12p)
and EDNRB1 (chromosome 13q). Frequency of deletion of FAT3 is
more by QPCR as compared to SNP array analysis, most likely due to it
being less speciﬁc than the array which incorporates more than one
primer set for each SNP. Loss of FAT3 expression in lung adenocarci-
nomas has been reported previously [43]. Ampliﬁcations in copies of
the RASSF8 locus (N3) were seen in 31% of the samples, making this
alterations less consistent with SNP array. Previous studies reported
contradictory results on RASSF8, one study found higher amount of
RASSF8 RNA in plasma and cell-bound fraction of patients with breast
cancer compared with patients with benign tumors and healthy
controls [44] while another group reported that RASSF8 gene
transcript levels were approximately seven-fold-lower in lung
adenocarcinomas as compared to normal lung tissue [45]. To
understand clearly the relationship between ampliﬁed and deleted
areas found by our analysis and function of relevant genes in SE
further studies using immunohistochemistry and/or RT-PCR need to
be performed. Discrepancies of copy number variations between SNP
analysis and QPCR may have many reasons; the most likely
explanations are software noise of both assays and different thresholdTable 6
Genomic location and associated genes of detectable loss of heterozygosity (LOH) regions i
Cytoband Start End Size (in Kb) No. of SNP i
2p15 63519189 63779097 259.908 11
2q21.3 135735952 135961986 226.034 11
2q21.3 136647841 136744005 96.164 5
2q32.2 189653052 189708407 55.355 7
2q35 219353217 219456470 103.253 7
3p26.3 416553 511456 94.903 11
4q13.3 75661840 75693143 31.303 5
5q21.3 109207920 10925834 50.714 5
8q11.21 50816259 50990529 174.27 20
11q24.1 122255254 122305361 50.107 5
13q12.3 28134226 28185843 51.617 12
18q12.2 31481579 31580034 98.455 8levels for cutoff. To understand the exact consistency between SNP
and QPCR analysis, other methods like FISH are required.
FAT3 is the human homolog of a tumor suppressor gene in
Drosophila. It has been suggested that FAT3 protein plays an important
role in axon fasciculation and modulation of the extracellular space
surrounding axons during embryonic development [46]. The protein
encoded by EDNRB is a G protein-coupled receptor which activates a
phosphatidylinositol–calcium second messenger system, and this
gene has been shown by our group to be epigenetically altered in oral
cancer [47]. ALKBH8 is a DNA repair molecule and has been correlated
with bladder cancer progression [48]. RASSF8 is reported as a lung
cancer tumor suppressor gene that regulates cell–cell adhesion and
actin cytoskeleton organization, inhibiting cell growth, playing a role
in the regulation of Wnt and NF-KB signaling pathways [49].
It is very important to elucidate the biological relevance of newly
identiﬁed potential TSGs and oncogenes in the pathogenesis of SEs.
However, a major limitation for studies of SEs is the lack of relevant
cell lines. To date there is only one cell line (TCam-2) that has been
characterized to be SEs [50]. There are no available normal cell lines
that represent the tissues fromwhere SEs developed, however there is
a mixed normal cell line called Hs.1.Tes. We performed RT-PCR
experiments to determine if the normal mixed cell line showed any
differences in expression compared to the one SE cell line (TCam-2).
We were unable to see any obvious mRNA expression differences of
our ampliﬁed or deleted genes in the TCam-2 and available NE cell
lines (data not shown), thus making functional studies not possible at
this moment. Interestingly, a recent study in TGCT comparing
genomic alterations and expression proﬁling found that a number of
regions of copy number changes did not always correlate with
expression [40].
Genomic instability has been correlated with progression in SEs
[51]. Our data suggest that CN deletions in chromosomes 4, 5, 9, 13,
and 20 and ampliﬁcations of chromosomes 9 and 13 correlate with
advanced stage of disease. Few studies have identiﬁed the underlying
genes involved in the pathogenesis of testicular cancer and identifying
the key genes critical for the pathogenesis of SE will be explored
within a larger sample group. Gain of chromosome 12p is suggested to
be a crucial event for the development of invasive disease. Genes on
chromosome 12 that have been suggested to be important for the
pathogenesis of TGCT include SOX5, JAW1 and K-RAS, among others
[52]. We found ampliﬁcations of chromosomal regions 12p12.1
harboring RASSF8. 28% of our samples had ampliﬁcations of this
region. Interestingly, regions 12p11.2 through 12p12.1 were previ-
ously identiﬁed as an ampliﬁed region supporting our ﬁndings [51].
LOH and HDs provide valuable information for identifying TSGs.
We found 30 HDs in the only stage III sample (SE23), those have not
been previously shown to play a role in the initiation of SE
development. HD of tumor suppressor DCC on chromosomal region
18q in SE has also been suggested to be associated with TGCT
progression [53]. The candidate tumor suppressors identiﬁed heren seminoma samples (probability threshold of 0.20).
n LOH area N (%) Gene Sample IDS
6/23(26) LOC51057,MDH1 15,21,2,5,6,8
5/23(22) RABGAP1, ZRANB3 19,21,3,9,17
5/23(26) CXCR4 19,21,8,9,20
5/23(26) (COL3A1) 19,21,8,16,20
6/23(26) BCSI1L, STK36,TTLL4 19,6,8,16,17,20
5/23(22) CHL1 11,4,7,18,20
5/23(22) AREG 15,21,8,16,17
5/23(22) MAN2A1 1,21,6,16,18
7/23(30) SNTG1 11,19,21,23,2,16,20
5/23(22) C11orf63, LOC79864 10,3,8,16,18
6/23(26) POMP, SLC46A3 15,21,8,16,17,18
5/23(22) GALNT1 1,22,6,9,16
348 C. LeBron et al. / Genomics 97 (2011) 341–349include UNC5C, CSMD1, and IMP8. The loss of UNC5C expression has
been observed in human colorectal cancer and is suggested to be a
selective advantage for tumor progression [54]. CSMD1 is a candidate
TSG in breast, upper aerodigestive tract, prostate, ovary and bladder
cancer [55,56]. Further studies including sufﬁcient number of stage III
tumors are essential to select candidate HD regions and to study the
biological function of related genes harboring in these area.
A major limitation in our study is the only one stage III tumor that
was available to us; therefore we could not determine whether the
homozygous deletions we found were representative of advanced
stage. However, our results provide important insight of chromosomal
instability relative to tumor progression. MiRNAs are often known to
exist in fragile genomic regions. Notably, one of our identiﬁed
candidates, IMP8 (chromosome 12) is required for binding of Ago
proteins to a variety of mRNA targets and that depletion of Imp8
interferes with miRNA-guided gene silencing [57]. Other HDs are
likely to point to the location of as yet unknown and probably
uncharacterized SE TSGs. Oncogenes can be identiﬁed by focal
ampliﬁcations and we detected 43 focal ampliﬁcations events in
eight of our samples. However, due to our limited sample size, we
were unable to detect common focal ampliﬁcation. Analysis of
additional samples will further justify these focal ampliﬁcations and
functional studies of the genes located in these focal ampliﬁcations
may be the fertile avenue to understand the biology of SEs.
SEs are radio and chemo-sensitive tumors and mostly curable at
each stage [25]. This sensitivity makes this tumor type an excellent
model for studying the mechanism of chemotherapy drug resistance
[58]. Relapse poses amajor challenge in treatment of different kinds of
cancer, mainly due to the lack of response to cisplatin-based
chemotherapy. The molecular mechanisms underlying this drug
resistance have not been fully elucidated but extensively studied.
Some genetic aberrations have been suggested as a potential pathway
to drug resistance. It has been reported that chromosomal ampliﬁca-
tions of regions 1q, 2p, 7q, 9q, 15q, 16q and 20q are associated with
cisplatin resistance in TGCT [59,60]. Interestingly, most of the novel
alterations in our study were found on chromosome 2q which encode
many genes involved in drug transport and DNA excision repair. The
drug transporter ATP dependent gene (ABCB6) is located in genomic
regions 2q35–36 which we report to have a SE speciﬁc ampliﬁcation.
This gene has been reported to have copy number gains that were
associated with cisplatin drug resistance in A549 lung cancer cells
[61]. Another gene of interest is the ERCC3, a DNA repair gene, which
we found to have copy number gains. Gene expression proﬁling has
linked TGCT resistance to cisplatin and high level expression of DNA
repair genes including ERCC1, XPA, ERCC2 and ERCC3 [60,62].
Correlation with response to cisplatin was not possible given the
fact that only one patient in our sample set was treated after surgical
removal of the primary tumor with the agent (SE14), therefore, we
will have to monitor this patient for longer periods of time to
determine if relapse occurs and what the consequence will be. In
addition, many ovarian carcinomas are resistant to cisplatin or
become resistant after recurrence. We will explore the potential of
identifying key genes that could be correlated with sensitivity or
resistance, by the comparison of SNP array data from testicular and
ovarian cancers. Although these are different tissue types and have
differential expressions of many genes due to tissue speciﬁcity, we
hypothesize that there is a key common component that determines
the ability of the cancer cell to survive in the presence of toxic
chemicals.
In summary, our study provides new insight into the genetic
alterations associated with SE. We found several novel copy number
ampliﬁcations and deletions of chromosome 2. We also identiﬁed
several chromosomes associated with progression of SE including
deletions of chromosomes 4, 5, 9, 13, and 20 and ampliﬁcations of
chromosomes 9 and 13. In addition, we discovered chromosomal
regions of LOH which could be critical for the development of SE;however these ﬁndings need further analysis and functional charac-
terization of any of the newly identiﬁed potential TSGs and oncogenes
need to be performed in future studies. 30 homozygous deletions
were found in our stage III sample and may contain potential
important TSG; however a combined functional study including
gene re-expression and immunohistochemistry remains to be
performed.
Here, we used high-density whole-genome SNP arrays (Affymetrix
250 K Nsp1 array), with an average inter-SNP distance of 5.8 kb to
deﬁne a comprehensive allelotype of SE based on LOH and copy
number changes. We identiﬁed several novel areas of ampliﬁcation
and deletion. It has been suggested that these areas of ampliﬁcation
and deletion may harbor relevant TSGs and oncogenes, respectively.
Further study will elucidate the relevance of these gains and losses
with different clinical parameters including drug resistance and
overall outcome of SE patients.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.02.011.References
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